Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + eribulin + veliparib
- Development stage
- Phase 2
- Lead developer
- UT Health San Antonio
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of eribulin mesylate (a microtubule dynamics inhibitor), carboplatin (a platinum-based DNA alkylating agent), and veliparib (a PARP inhibitor). The regimen is being investigated by The University of Texas Health Science Center at San Antonio in a Phase II clinical trial for patients with Stage IV (metastatic) breast or ovarian cancer who exhibit homologous recombination deficiency (HRD) or BRCA mutations. Eribulin inhibits the growth phase of microtubules without affecting the shortening phase, leading to cell cycle arrest. Carboplatin creates DNA crosslinks, and veliparib prevents the repair of these DNA lesions by inhibiting poly(ADP-ribose) polymerase (PARP) enzymes, potentially creating a synergistic effect in HRD-positive tumors.
- Other names
- Carboplatin, Eribulin, and Veliparib combinationEribulin, Carboplatin, and Veliparib
02
Targets
DNAPARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)Pol II (RNA polymerase II elongation factors)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on carboplatin + eribulin + veliparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + eribulin + veliparib.